The Latest Crohns Disease Industry Statistics Explained
Approximately 1.6 million Americans currently have Inflammatory Bowel Disease, which includes Crohn’s disease.
The statistic that approximately 1.6 million Americans currently have Inflammatory Bowel Disease (IBD), which includes conditions like Crohn’s disease, indicates a significant prevalence of these chronic inflammatory disorders in the United States. IBD encompasses diseases that cause inflammation in the digestive tract and can lead to various symptoms and complications, affecting the quality of life of those diagnosed. Crohn’s disease, a type of IBD, is characterized by inflammation that can occur anywhere in the gastrointestinal (GI) tract, leading to abdominal pain, diarrhea, fatigue, and other debilitating symptoms. The high number of individuals affected by IBD highlights the importance of continued research, awareness, and support for those living with these conditions.
Between 2011 and 2015, the prevalence of Crohn’s disease in the United States fluctuated around 201 per 100,000 population.
The statistic indicates that between the years 2011 and 2015, the prevalence of Crohn’s disease in the United States remained relatively stable around an average of 201 cases per 100,000 people. This means that over this time period, there were fluctuations in the number of reported cases of Crohn’s disease, but on average, it was consistently around 201 cases per 100,000 individuals in the population. This information highlights the overall prevalence of the disease during those years and can provide insights into the burden of Crohn’s disease on the healthcare system and society as a whole.
In the United States, in 2019, the number of visits to physician offices with Crohn’s disease as the primary diagnosis was 336,000.
In the United States in 2019, there were a total of 336,000 visits to physician offices where Crohn’s disease was documented as the primary diagnosis. This statistic represents the significant number of individuals seeking medical care for Crohn’s disease, a chronic inflammatory bowel disease that can have a substantial impact on a person’s quality of life. The data provides valuable insights into the prevalence and healthcare burden of Crohn’s disease in the U.S., highlighting the importance of effective management and treatment strategies for individuals affected by this condition.
As of 2020, North America dominates the Crohn’s disease market with a share of nearly 41%.
The statistic indicates that as of 2020, North America holds a significant market share in the Crohn’s disease pharmaceutical market, accounting for nearly 41% of the total market. This dominance suggests that North America, comprised of countries such as the United States and Canada, has a strong presence in the treatment and management of Crohn’s disease compared to other regions globally. Factors contributing to this domination may include higher prevalence rates of Crohn’s disease in North America, advanced healthcare infrastructure, access to innovative therapies, and robust research and development activities within the region. This statistic underscores the importance of North America in the Crohn’s disease market landscape and highlights opportunities for targeted interventions and collaborations to address the needs of Crohn’s disease patients in the region.
Biologics dominate the Crohn’s disease treatment market and accounted for 55.9% of the total market share in 2020.
The statistic ‘Biologics dominate the Crohn’s disease treatment market and accounted for 55.9% of the total market share in 2020’ indicates that biologic medications, which are derived from living organisms, hold a significant portion of the market for treating Crohn’s disease, a chronic inflammatory bowel condition. The dominance of biologics suggests that these advanced treatments are widely adopted by healthcare providers and patients due to their effectiveness in managing symptoms and improving quality of life for individuals with Crohn’s disease. The fact that biologics accounted for over half of the market share reflects their increasing importance and popularity in the treatment landscape for this condition in 2020.
By 2030, it is estimated that the prevalence of Crohn’s disease will be nearly 819,000 in the United States alone.
The statistic that by 2030, the prevalence of Crohn’s disease is estimated to be nearly 819,000 in the United States alone indicates the projected number of individuals affected by this inflammatory bowel disease. Crohn’s disease is a chronic condition that causes inflammation of the digestive tract, leading to symptoms such as abdominal pain, diarrhea, fatigue, and weight loss. The estimated prevalence of 819,000 cases by 2030 highlights the increasing burden of this disease on the U.S. healthcare system and underscores the importance of effective management strategies and interventions to support those living with Crohn’s disease and to reduce its impact on individuals and society.
The global Crohn’s disease therapeutics market is projected to grow at a CAGR of 4.1% between 2021-2028.
This statistic indicates that the global Crohn’s disease therapeutics market is expected to experience a compound annual growth rate (CAGR) of 4.1% over the period from 2021 to 2028. This suggests that the market for medications and treatments targeting Crohn’s disease is forecasted to expand steadily over the specified timeframe. A CAGR of 4.1% signifies a moderate growth rate, which could potentially be influenced by factors such as the increasing prevalence of Crohn’s disease, advancements in treatment options, evolving healthcare systems, and growing awareness among both patients and healthcare providers. Overall, this projection indicates a favorable outlook for the Crohn’s disease therapeutics market in the coming years.
Among pharmaceuticals, Johnson & Johnson, AbbVie Inc., and Gilead Sciences Inc. are the leading players in the Crohn’s disease market.
The statistic indicates that among pharmaceutical companies operating in the Crohn’s disease market, Johnson & Johnson, AbbVie Inc., and Gilead Sciences Inc. are the top leaders in terms of market share, sales, or overall influence in the industry. This suggests that these companies have a significant presence in developing and marketing treatments for Crohn’s disease, a chronic inflammatory bowel condition. Their prominence in this market may be attributed to the efficacy of their products, strong marketing strategies, extensive research and development efforts, or other competitive advantages. Overall, the statistic highlights the key players in the Crohn’s disease pharmaceutical sector and provides valuable insights into the competitive landscape of this specific market segment.
There has been a steady increase in IBD-related hospitalizations, including Crohn’s disease, with an average increase of 4.3% each year.
The statistic indicates that there has been a consistent rise in hospitalizations related to inflammatory bowel disease (IBD), specifically Crohn’s disease, over a period of time. The average annual increase in IBD-related hospitalizations is reported to be 4.3%, suggesting a gradual but significant escalation in the number of individuals seeking medical care for IBD conditions. This trend highlights a concerning pattern of higher healthcare utilization for these conditions, potentially indicating a growing burden of IBD on healthcare systems and emphasizing the importance of effective management and treatment strategies for individuals with Crohn’s disease and other forms of IBD.
The annual direct cost of Crohn’s disease in the United States is estimated to be $3.6 billion.
The statistic that the annual direct cost of Crohn’s disease in the United States is estimated to be $3.6 billion represents the total monetary expenses incurred from the treatment and management of Crohn’s disease within a one-year period. This figure includes costs associated with healthcare services such as hospitalizations, medications, doctor visits, surgeries, and diagnostic tests specific to Crohn’s disease. The cost accounts for the financial burden on individuals, insurance companies, and government healthcare programs. Understanding the economic impact of Crohn’s disease is essential for healthcare policy and resource allocation to address the challenges faced by individuals with this chronic condition and to improve overall health outcomes and quality of life.
Patients with Crohn’s disease in the United States lose an average of 11.2 workdays per year due to the disease.
The statistic “Patients with Crohn’s disease in the United States lose an average of 11.2 workdays per year due to the disease” indicates the impact of this chronic inflammatory bowel disease on individuals’ ability to work. Crohn’s disease is known to cause symptoms such as abdominal pain, diarrhea, fatigue, and other complications, which can significantly impact patients’ quality of life and ability to carry out their regular work responsibilities. The average of 11.2 workdays lost per year highlights the burden of this condition on the productivity and employment status of affected individuals, emphasizing the need for effective management strategies and support systems to help alleviate the impact of the disease on patients’ daily lives.
In 2020 Europe had the second largest Crohn’s disease market after North America.
The statistic implies that in 2020, Europe ranked second in terms of the size of the market for Crohn’s disease pharmaceuticals and treatments, following North America. This suggests that Europe is a significant market for Crohn’s disease-related products and services, with a substantial number of patients in the region requiring medical treatment and care for this inflammatory bowel disease. The ranking indicates that Europe is an important region for companies in the healthcare industry to focus on in terms of developing and marketing Crohn’s disease treatments, alongside North America, due to the potential market size and demand for such products in the region.
Anti-inflammatory drugs segment was the leading segment in Crohn’s disease market in 2020.
The statistic “Anti-inflammatory drugs segment was the leading segment in Crohn’s disease market in 2020” indicates that among all the categories of drugs used to treat Crohn’s disease, anti-inflammatory drugs had the highest market share in terms of revenue or sales volume in the year 2020. This suggests that there was a higher demand for anti-inflammatory drugs compared to other types of medications within the Crohn’s disease market during that time period. This information is valuable for industry stakeholders, healthcare providers, and researchers to understand the prevailing trends and preferences in the treatment of Crohn’s disease, which can inform decision-making related to product development, marketing strategies, and patient care.
The annual mean health expenditure per person for Crohn’s disease in the US is around $8,265.
The statistic regarding the annual mean health expenditure per person for Crohn’s disease in the US being around $8,265 implies the average amount of money spent on healthcare per individual diagnosed with Crohn’s disease in a given year. This figure takes into account various costs associated with managing the disease, including physician visits, medications, hospitalizations, surgeries, and other related expenses. The significance of this statistic lies in highlighting the financial burden placed on individuals, families, insurance companies, and the healthcare system as a whole due to the high costs of managing Crohn’s disease. It underscores the importance of access to affordable healthcare and the need for effective strategies to mitigate healthcare expenses for individuals living with chronic conditions like Crohn’s disease.
The annual treatment cost per patient for Crohn’s disease can be up to $18,963 in the US.
The statistic indicates that the average annual treatment cost per patient for Crohn’s disease in the United States can reach as high as $18,963. This figure encompasses various expenses associated with managing the disease, including medications, doctor visits, hospitalizations, and other medical services. The cost of treating Crohn’s disease can vary depending on factors such as the severity of the condition, the type of treatments needed, insurance coverage, and geographical location. The high annual cost highlights the significant financial burden that individuals with Crohn’s disease may face in accessing necessary healthcare services and underscores the importance of understanding and addressing the economic challenges associated with managing this chronic condition.
The Asia-Pacific Crohn’s disease market is expected to grow at the highest CAGR during the forecast period (2020-2030).
The statistic indicates that the Asia-Pacific Crohn’s disease market is projected to experience the highest Compound Annual Growth Rate (CAGR) during the forecast period from 2020 to 2030. This suggests that the market for Crohn’s disease-related products and services in the Asia-Pacific region is anticipated to expand at a faster pace compared to other regions. Factors such as increasing awareness about the disease, improving healthcare infrastructure, rising prevalence of Crohn’s disease, and advancements in treatment options could be driving this growth. This trend signifies potential opportunities for companies operating in the Crohn’s disease market to focus on the Asia-Pacific region for market expansion and investment.
References
0. – https://www.www.bizjournals.com
1. – https://www.www.globenewswire.com
2. – https://www.www.prnewswire.com
3. – https://www.www.mordorintelligence.com
4. – https://www.www.healio.com
5. – https://www.www.futuremedicine.com
6. – https://www.www.cdc.gov
7. – https://www.www.transparencymarketresearch.com
8. – https://www.www.ncbi.nlm.nih.gov
9. – https://www.www.fortunebusinessinsights.com
10. – https://www.www.crohnscolitisfoundation.org
11. – https://www.www.researchandmarkets.com
12. – https://www.pubmed.ncbi.nlm.nih.gov
